Trial · NCT06333314
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
NCT06333314, Phase 2, Recruiting, UNICANCER
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI. Trials, record NCT06333314. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06333314
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
- NCT number
- NCT06333314
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 120 participants, estimated
- Lead sponsor
- UNICANCER
- Conditions
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
- Interventions
- Dostarlimab, Chemotherapy
- First posted
- 2024-03-27
- Last updated
- 2025-12-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | From randomization until disease progression or death from any cause, up to 3 years. | The progression-free survival is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. |
| Secondary | Objective Response Rate | From randomization to disease progression or death, up to 3 years | Objective Response Rate is defined as the proportion of patients with best response of complete response (CR) or partial response (PR) according to RECIST v1.1. |
| Secondary | Duration of response | From randomization to disease progression or death, up to 3 years | Duration of response (DOR) will be evaluated in patients with either a complete response (CR) or partial response (PR). DOR is defined as the time from the first assessment of a CR or PR until the date of the first occurrence of progressive disease (PD) or death from any cause (if death occurred within predefined period), whichever occurs first. |
| Secondary | Overall Survival | From randomization until death from any cause, up to 3 years | The overall survival is the length of time from randomization that patients enrolled in the study are still alive. |
| Secondary | Progression-Free Survival 2 | From randomization to disease progression or death, up to 3 years | Progression-Free Survival 2 (PFS2) is defined as the time from randomization to second/subsequent disease progression after initiation of new anti-cancer therapy (including subsequent immune checkpoint inhibitor therapy), or death from any cause, whichever first. |
| Secondary | Objective response rate 2 | From randomization to disease progression or death, up to 3 years | Objective response rate after initiation of new anti-cancer therapy (ORR2) is defined as the proportion of patients with best response of CR or PR according to the investigator's judgment. |
| Secondary | Progression-Free Survival -crossover | From randomization to disease progression or death, up to 3 years | Progression-free survival - crossover is defined as the time from crossover initiation to disease progression after initiation of new anti-cancer therapy, or death from any cause, whichever first. |
| Secondary | Circulating tumor DNA level | From randomization to disease progression or death, up to 3 years | The evolution of circulating tumor DNA (ctDNA) level in patient's blood during treatment will be correlated with PFS in the overall population. |
| Secondary | Incidence of treatment-emergent adverse events | Throughout study completion, up to 3 years | The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. |
| Secondary | Quality of life questionnaire - Core 30 (QLQ-C30) | At baseline, every 2 or 3 weeks, and at the end of treatment (up to 2 years) | Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06333314
GET https://conductscience.org/api/trials/v1/NCT06333314/registered